Back to search

Article

Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59

2024-08-22

Abstract excerpt

<title>Abstract</title> <p>Background: The COVID-19 pandemic led to the development of many vaccines, most notably the mRNA and recombinant adenoviral vaccines. Whilst the vaccines proved to be effective in preventing severe COVID disease, they failed to prevent infection or to control the ongoing emergence of vaccine escape variant viruses. The rapid waning of vaccine induced antibody responses has also necessit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
462596ef-e589-594e-914b-0b7bc56f8413
DOI
10.21203/rs.3.rs-4503306/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59DOI 10.21203/rs.3.rs-4503306/v1
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersSemantic proximity
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA ConsortiumSemantic proximity
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity
Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity
First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2Semantic proximity
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variantsSemantic proximity
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccineSemantic proximity
Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P VaccineSemantic proximity
An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaquesSemantic proximity
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity
Select a neighboring publication to make it the new centre.